Cortexyme, Inc. Aktie News
0,96 $
3,36 %
Nasdaq,
Do, 02.05.2024
tracken
Cortexyme, Inc. Aktie News
Neutral
PRNewsWire
●
etwa 2 Jahre alt
NEW YORK , April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
Neutral
PRNewsWire
●
etwa 2 Jahre alt
NEW YORK, April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
Neutral
PRNewsWire
●
etwa 2 Jahre alt
NEW YORK, March 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be ent...
Neutral
PRNewsWire
●
etwa 2 Jahre alt
NEW YORK , Feb. 16, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cortexyme securities you may be ent...
Neutral
PRNewsWire
●
mehr als 2 Jahre alt
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S.
Negativ
Schaeffers Research
●
mehr als 2 Jahre alt
Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
Negativ
The Motley Fool
●
mehr als 2 Jahre alt
The FDA's latest move regarding one of this biopharma's investigational drugs all but slams the door shut on its future.
Negativ
The Motley Fool
●
mehr als 2 Jahre alt
A key clinical setback sent investors to the exits last year.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
